17/12/2007 (Agence Europe) - The European Medicines Agency has called for the withdrawal of all products containing lumiracoxib, a COX-2 inhibitor. This non-steroid anti-inflammatory has a hepatotoxicity rate which makes the benefit/risk ratio unfavourable. This product, which was launched in 2005, is used for the relief of certain types of arthritis, was available in 24 European countries under the trade names Prexigen, Stellige, Hirzia and Frexocel. The authorisation for this active...